Sugi Predict

Sugi Predict / Compounds / SCHEMBL5330174

SCHEMBL5330174

SCHEMBL5330174

CCOC(=O)C(C)C(=O)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MMP8 P22894 2/20 0.49
▸ PIN1 Q13526 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ MAPK8 P45983 1/20 0.45
▸ MAPK9 P45984 1/20 0.45
▸ MAPK10 P53779 1/20 0.45
▸ MAPK1 P28482 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CES2 O00748 1/20 0.44
▸ CES1 P23141 1/20 0.44
▸ AKR1B1 P15121 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23686780 0.86 KMT2A (0.49) L3MBTL1LMNAMEN1NPC1KMT2A
SCHEMBL11847351 0.84 PTGS2 (0.46) L3MBTL1LMNAMEN1NPC1KMT2A
SCHEMBL13495167 0.84 MMP8 (0.50) TSHRL3MBTL1LMNAMMP8PIN1
SCHEMBL3344796 0.83 MAPT (0.49) L3MBTL1LMNANPC1ALDH1A1POLB
SCHEMBL1287178 0.83 TSHR (0.47) TSHRL3MBTL1LMNAMMP8PIN1
SCHEMBL16049191 0.81 MMP8 (0.55) TSHRL3MBTL1LMNAMMP8PIN1
SCHEMBL3690028 0.81 MMP8 (0.48) TSHRL3MBTL1LMNAMMP8PIN1
SCHEMBL4780672 0.81 ALOX5 (0.52) L3MBTL1LMNANPC1SMN1; SMN2MAPK1
SCHEMBL10988462 0.80 TSHR (0.50) TSHRMEN1NPC1KMT2APOLB
Hydrochloric Acid SCHEMBL11328850 0.80 PIN1 (0.49) TSHRL3MBTL1LMNAMMP8PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
EP-4322954-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2024-02-21 — — EP disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
US-20150344398-A1 4-HYDROXYBUTYRIC ACID ANALOGS SUN PHARMACEUTICAL INDUSTRIES, INC. 2015-12-03 — — US disclosed
WO-2007144625-A1 2-OXO-2H-CHROMENE COMPOUNDS ARGENTA DISCOVERY LIMITED (GB) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885L3MBTL1 2112/4885LMNA 2991/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TSHR 4273/4885L3MBTL1 2112/4885LMNA 2991/4885
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS TSHR 4424/4885L3MBTL1 3599/4885LMNA 4027/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885L3MBTL1 2112/4885LMNA 2991/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885L3MBTL1 2112/4885LMNA 2991/4885
US-20150344398-A1 4-HYDROXYBUTYRIC ACID ANALOGS HCRTR2, HCRTR1, HTR2B TSHR 3133/4885L3MBTL1 1782/4885LMNA 3598/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885L3MBTL1 2112/4885LMNA 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.